Rhythm Pharmaceuticals Q1 Earnings Call Highlights

Key Points

• Rhythm reported $60.1 million in global net revenues for Q1 2026, a 5% sequential increase with $341 million in cash to fund operations for at least 24 months, while maintaining 2026 non‑GAAP operating expense guidance of $385–$415 million and recording a GAAP loss of $0.83 per share.
• The U.S. commercial launch for IMCIVREE in acquired hypothalamic obesity shows early traction with over 150 start forms and roughly 110 unique prescribers in six weeks (about 80% new), supported by an expanded U.S. sales force (from 16 to 42 reps) and encouraging early payer receptivity though HO‑specific policies may take 3–9 months to establish.
• International progress accelerated: the European Commission granted marketing authorization for acquired HO with launches expected in 2027, and Japan’s PMDA has accepted the NDA with Rhythm anticipating approval and launch by the end of 2026 (Japan patient estimate: 5,000–8,000).

Rhythm Pharmaceuticals NASDAQ: RYTM reported first-quarter 2026 revenue growth as the company began its U.S. commercial launch of IMCIVREE for acquired hypothalamic obesity (HO) and highlighted new regulatory progress in Europe and Japan.

First-quarter results show continued IMCIVREE growth

Chairman, CEO, and President David Meeker said the company delivered “another good quarter,” led by continued momentum in its base business, particularly Bardet-Biedl syndrome (BBS). Hunter Smith, Rhythm’s CFO, reported $60.1 million in global net revenues from IMCIVREE in Q1 2026, representing 5% sequential growth versus Q4 2025. Smith added that 61% of revenue was generated in the United States, with the remainder generated outside the U.S.

Smith said global patients on reimbursed therapy increased 8% quarter-over-quarter, “driven primarily by BBS.” He also detailed factors affecting U.S. revenue comparisons, including a specialty pharmacy inventory increase in Q4 2025 that “pulled sales forward,” and the seasonal impact of patients transitioning insurance plans early in the year. Jennifer Lee, EVP and head of North America, said those insurance transitions led to a temporary increase in patients receiving free drug through Rhythm’s Bridge Program, but “as of mid-April,” most had transitioned back to reimbursed therapy.

Outside the U.S., Smith reported revenue increased from $18.3 million to $23.2 million, a 27% sequential increase, driven by increased sales volumes in Germany and France and certain named patient markets including Saudi Arabia and Greece. He noted some named patient markets can create more variable quarterly revenue due to longer lead times.

On expenses, Smith reported:

• R&D expenses of $41.7 million (vs. $37.0 million in Q1 2025), with the year-over-year increase primarily due to higher headcount-related costs.
• SG&A expenses of $63.6 million (vs. $39.1 million in Q1 2025), reflecting higher headcount-related costs and marketing activities supporting the acquired HO launch.
• GAAP EPS net loss of $0.83 per basic and diluted share, including $0.02 per share from accrued dividends on convertible preferred stock.
• Cash used in operations of approximately $44.2 million for the quarter.

Rhythm ended Q1 with approximately $341 million in cash, cash equivalents, and certain term investments, which Smith said the company expects will fund planned operations for “at least 24 months.” The company maintained its 2026 non-GAAP operating expense guidance of $385 million to $415 million.

Acquired HO launch ramps with early start forms and broad prescriber base

Rhythm’s March 19 FDA approval for IMCIVREE in acquired HO expanded the company’s commercial focus beyond BBS. Meeker said the early launch is “extremely early,” but the company is “pleased with a strong start with more than 150 start forms to date and a good reception at the payer level.”

Lee said the company has received more than 150 start forms in the six weeks since approval, including approximately 40 for clinical trial patients. She added that there have been approximately 110 unique prescribers for acquired HO during the first six weeks, and about 80% were new prescribers of IMCIVREE. Lee said roughly 80% of early prescribers were endocrinologists, along with some pediatricians and primary care physicians.

Lee noted the acquired HO market is more concentrated than BBS and estimated the prevalence at approximately 10,000 patients in the U.S. and Europe. To support the broader opportunity, she said Rhythm expanded its U.S. commercial footprint from 16 sales reps for BBS to 42 sales reps, and also scaled its patient services team.

On reimbursement, Lee said early payer receptivity has been encouraging, particularly among payers already familiar with IMCIVREE through BBS coverage. However, she cautioned Rhythm still expects it will take approximately three to nine months from approval for HO-specific IMCIVREE policies to be established.

Asked about patient identification efforts, Lee said the company’s previously referenced patient pool has “continued to increase” since the company discussed it last year, but she said Rhythm is no longer updating that figure and is instead focusing on launch metrics such as start forms. She added that “the vast majority” of start forms have come from physicians Rhythm engaged with prior to approval.

Meeker said the rate of start forms in HO has been higher than Rhythm saw in the first six weeks of the BBS launch, while also cautioning that BBS is not a perfect comparison due to differences in population size and physician concentration. He later reiterated management’s view that the HO launch is broad-based, saying it is “not a launch where we’ve got two or three believers…writing a bunch of scripts.”

Lee said the “vast majority” of early acquired HO patients have tumor or tumor treatment-related backgrounds, but the label is broader and includes other causes such as stroke, traumatic brain injury, or inflammation, and the company has received prescriptions reflecting that broader mix.

Europe receives HO authorization; launches anticipated to begin in 2027

Yann Mazabraud, EVP and head of international, said the European Commission granted marketing authorization for IMCIVREE for obesity and control of hunger in patients four years and older with acquired HO due to hypothalamic injury or impairment. Mazabraud said the CHMP opinion came sooner than expected, and marketing authorization followed one month later.

Mazabraud said Rhythm has begun country-level market access work, with launches anticipated to begin in 2027. He outlined steps in Germany, including seeking an exemption from the G-BA exclusion list for lifestyle drugs, a process he said can take six to nine months and could support a 2027 launch. He also said key local reimbursement dossiers are finalized and negotiations will begin in France, Italy, Spain, and other countries.

In the U.K., Mazabraud said Rhythm submitted to the MHRA via the International Recognition Procedures based on the CHMP opinion. He also cited ongoing enthusiasm supported by reimbursed early access programs for HO in France and Italy, which he said represent a meaningful portion of international-region reimbursed therapy. He noted that French physicians are expected to present real-world data from “more than 60 patients” in the French early access program at the European Congress of Endocrinology, including a cohort treated for up to 12 months.

Japan filing accepted; Rhythm anticipates approval and launch by end of 2026

Rhythm also discussed its path toward Japan, which Meeker described as a major opportunity behind the U.S. in acquired HO. Mazabraud said the company estimates 5,000 to 8,000 patients with acquired HO in Japan and emphasized strong KOL support and engagement with regulators. He said Rhythm now has “almost 50 employees in Japan” and is executing pre-launch tactics focused on disease awareness and patient identification.

The company announced that Japan’s PMDA has accepted and is reviewing Rhythm’s NDA filing for IMCIVREE in acquired HO. While Japanese regulators do not publish a formal timeline, Mazabraud said Rhythm anticipates approval and launch by the end of 2026. He added the company has identified 151 Tier 1 hospitals with the highest volume of brain tumor surgeries, which are being visited by the Japanese field force.

Pipeline and upcoming milestones include PWS data and next-generation programs

Meeker said Rhythm expects several milestones in 2026, including an anticipated presentation of Dr. Miller’s six-month data in Prader-Willi syndrome (PWS) at the ENDO meeting in June, pending abstract acceptance. He said Rhythm expects to share BMI data, HQ-CT data, and DEXA scan data for patients who have completed scans. Meeker also said the company anticipates sharing RM-718 data mid-year and is targeting the Q2 earnings call to share Part C results in HO and potentially available data in PWS.

In the Q&A, Meeker said Rhythm believes MC4R biology in PWS supports both reduced hunger and increased energy expenditure, with an expected net effect of reduced weight. He said the company would aim to seek a PWS label that includes both hyperphagia reduction and weight/BMI reduction, noting Rhythm has previously obtained hunger reduction language in its European label for other indications.

Meeker closed by emphasizing three strategic pillars: continued work in genetic MC4R pathway impairment, expansion in hypothalamic obesity, and progress in PWS, alongside lifecycle management and early research programs, including a CHI program. He said the company remains cautious about forecasting rare disease launches but reiterated management is “really pleased with the start” in acquired HO.

About Rhythm Pharmaceuticals NASDAQ: RYTM

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.